We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

User:Carson Powers/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 30: Line 30:
==AHB2==
==AHB2==
-
<scene name='10/1076041/Ahb2_only/2'>AHB2</scene>is a stable miniprotein inhibitor that competes with the ACE2 receptor. It was developed using the Rosetta blueprint builder that incorporates the alpha helix in ACE2 (residues 23-46) into small, stable protein scaffolds. <scene name='10/1076041/Ahb2_interactions/1'>Along with making similar interactions with the spike protein, AHB2 includes additional interactions to increase its affinity.</scene> This allows it to compete with the ACE2 receptor effectively, preventing it from binding with the spike protein and the virus from infecting host cells.
+
<scene name='10/1076041/Ahb2_only/2'>AHB2</scene> is a stable miniprotein inhibitor that competes with the ACE2 receptor. It was developed using the Rosetta blueprint builder that incorporates the alpha helix in ACE2 (residues 23-46) into small, stable protein scaffolds. <scene name='10/1076041/Ahb2_interactions/1'>Along with making similar interactions with the spike protein, AHB2 includes additional interactions to increase its affinity.</scene> This allows it to compete with the ACE2 receptor effectively, preventing it from binding with the spike protein and the virus from infecting host cells.

Revision as of 02:23, 14 April 2025

De novo miniprotein Covid therapeutic

LCB1 bound to spike protein. LCB1 is colored pink and shown in cartoon. The spike protein is colored by chain and shown by its surface. PDB file: 7jzl

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Carson Powers

Personal tools